Physician profile
Sadeer Hannush
NPI 1780637942
$32,645.12
in general payments reported to CMS, 2019-2025
19 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,368 · 2020: $88.62 · 2021: $22K · 2022: $3,298 · 2023: $223 · 2024: $1,937 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,467 · Consulting Fee: $1,400 · Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,467.00 |
| Consulting Fee | $1,400.00 |
| Food and Beverage | $954.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Research Institute, INC. | $29,100.00 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $1,467.00 | 2025 | |
| Biotissue Holdings INC. | $344.08 | 2020-2024 | |
| Sight Sciences, INC. | $261.18 | 2021-2022 | |
| Alcon Vision LLC | $244.91 | 2022-2025 | Clareon |
| Rxsight INC | $234.38 | 2021-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbott Laboratories | $215.60 | 2021-2024 | Octrode |
| Kowa Company, Ltd. | $210.85 | 2019 | |
| Carl Zeiss Meditec, INC. | $106.19 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $79.18 | 2019 | |
| Eyepoint US, INC. | $78.00 | 2019 | |
| Dompe US, INC. | $70.85 | 2024 | Oxervate |
| Genentech USA, INC. | $70.24 | 2024-2025 | Vabysmo |
| Thea Pharma INC. | $59.61 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $43.18 | 2024 | Artevo 800 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $29.91 | 2024 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $16.43 | 2024 | Syfovre |
| Bausch & Lomb Americas INC. | $13.53 | 2024 | Xiidra, Miebo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$149,904.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadeer Hannush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.